MedTrace Logo

A IIT Study of 177Lu-DOTA-SNA040

NCT07595237 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-19

No results posted yet for this study

Summary

This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced Claudin18.2-positive solid tumors (e.g., gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer, cholangiocarcinoma, etc.) who have disease progression following first-line therapy.

Conditions

  • Advanced Solid Tumors (Such as Gastric Cancer)
  • Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
  • Advanced Solid Tumors (Such as Pancreatic Cancer)
  • Advanced Solid Tumors (Such as Cholangiocarcinoma)

Interventions

DRUG

177Lu-DOTA-SNA040

177Lu-DOTA-SNA040 administration

Sponsors & Collaborators

  • SmartNuclide Biopharma

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2025-11-24
Completion
2027-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07595237 on ClinicalTrials.gov